Catalog No.
Product Name
Application
Product Information
Citations
-
BChE Inhibitor
Blestrin D is a potent mixed-type inhibitor of butyrylcholinesterase (BChE), exhibiting an IC50 value of 8.1 μM. Isolated from Bletilla striata, this compound is valuable for investigating the biochemical pathways involved in Alzheimer's disease (AD). Its ability to inhibit BChE makes it an important tool for studying cholinergic dysfunction associated with neurodegenerative conditions. -
AChE Inhibitor
AChE-IN-22 is a selective inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), exhibiting IC50 values of 0.88 μM and 10 μM, respectively. This compound interacts with both the catalytic active site (CAS) and peripheral anionic site (PAS) of AChE, making it a valuable tool for studies related to Alzheimer's disease. AChE-IN-22 is suitable for research applications focused on cholinergic system modulation and neurodegenerative disease mechanisms. -
Cholinesterase (ChE) Inhibitor
eeAChE-IN-2 is a highly potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 2 nM. This compound serves as a valuable tool for studying cholinergic signaling and its modulation in various biological systems. Its application extends to research on neurodegenerative disorders and cognitive function, where AChE inhibition plays a critical role. -
AChE/BChE Inhibitor
AChE/BChE-IN-5 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 266 nM and 10.6 nM against human AChE (hAChE) and human BChE (hBChE), respectively. This compound is capable of crossing the blood-brain barrier (BBB), making it significant for research in neurodegenerative diseases and cognitive disorders. It serves as a valuable tool for studying the modulation of cholinergic signaling and the potential therapeutic effects in conditions such as Alzheimer's disease. -
AChE Inhibitor
Isonaringin is an acetylcholinesterase (AChE) inhibitor that demonstrates potential anti-Alzheimer's activity. By inhibiting AChE, Isonaringin increases acetylcholine levels in the brain, which may help improve cognitive function in neurodegenerative conditions. This compound is relevant for research applications focused on Alzheimer's disease and other related disorders. -
AChE Inhibitor
Zifrosilone is an orally active acetylcholinesterase (AChE) inhibitor, exhibiting a mean maximum inhibition of 20.9% at a dosage of 10 mg. This compound is useful in the study of neurological disorders, providing a valuable tool for research into conditions related to cholinergic dysfunction. Its selective targeting of AChE makes it an important reagent for investigating therapeutic strategies in neurodegenerative diseases. -
AChE Inhibitor
Ambenonium dichloride tetrahydrate is a potent, orally active, reversible inhibitor of acetylcholinesterase (AChE). This compound demonstrates a high affinity for human AChE, with an IC50 value of 0.7 nM, making it valuable for investigations into cholinergic system modulation. Its primary applications include the study of neurodegenerative diseases such as myasthenia gravis and Alzheimer's disease, as well as broader neuropharmacological research. -
BuChE Inhibitor
BuChE-IN-1 is a potent inhibitor of butyrylcholinesterase (BuChE), a key enzyme implicated as a biomarker in the progression of Alzheimer’s disease (AD). This compound exhibits low cytotoxicity and demonstrates excellent permeability across the blood-brain barrier (BBB). BuChE-IN-1 is an advantageous tool for investigating the role of BuChE in AD research and exploring therapeutic interventions. -
AChE Inhibitor
K027 is a potent reactivator of acetylcholinesterase (AChE) inhibited by organophosphates (OP). It effectively restores AChE activity, making it valuable for studying neurodegenerative conditions such as Alzheimer's disease. K027's mechanism and specificity provide a useful tool for investigating therapeutic strategies targeting cholinergic dysfunction. -
Cholinesterase (ChE) Inhibitor
hAChE-IN-4 is a potent inhibitor of human acetylcholinesterase (hAChE) with an IC50 value of 0.25 μM, demonstrating effective permeability across the blood-brain barrier. This compound plays a significant role in research related to Alzheimer's disease, where modulation of cholinergic activity is critical. Its use can aid in exploring therapeutic strategies targeting cholinesterase activity in neurodegenerative disorders. -
AChE Inhibitor
AChE-IN-26 is an acetylcholinesterase (AChE) inhibitor with a reported IC50 of 0.42 μM. This compound plays a significant role in research related to Alzheimer's disease by inhibiting the breakdown of acetylcholine, thereby enhancing cholinergic transmission. AChE-IN-26 serves as a valuable tool for studying pathophysiological mechanisms associated with neurodegeneration and for evaluating potential therapeutic strategies. -
Cholinesterase Inhibitor
Magnotriol B is a potent cholinesterase inhibitor, demonstrating IC50 values of 12.63 nM against acetylcholinesterase (AChE) and 14.5 nM against butyrylcholinesterase (BChE). Additionally, it exhibits notable nitric oxide (NO) inhibitory activity, with an IC50 of 2.02 μM. This compound is applicable in research focused on neurodegenerative disorders and inflammatory diseases, offering potential insights into therapeutic strategies targeting cholinergic dysfunction. -
AChE Inhibitor
Chikusetsusaponin Ib is a potent inhibitor of acetylcholinesterase (AChE), a key enzyme involved in neurotransmission. This compound exhibits significant anti-Alzheimer's disease activity, making it a valuable tool for research focused on neurodegenerative disorders. Its ability to modulate AChE activity can aid in the exploration of therapeutic strategies aimed at enhancing cognitive function and addressing Alzheimer’s pathology. -
AChE Inhibitor
Picfeltarraegenin X is a triterpenoid that functions as an acetylcholinesterase (AChE) inhibitor. This compound exhibits notable biological activity by enhancing acetylcholine levels, making it relevant for studies focused on neurodegenerative disorders such as Alzheimer's disease. Picfeltarraegenin X is useful in research applications aimed at understanding cholinergic signaling and developing potential therapeutic strategies targeting cognitive decline. -
Cholinesterase (ChE)
(Rac)-TZ3O primarily targets cholinesterase (ChE) and acts as an anticholinergic compound with neuroprotective properties. This compound has demonstrated the ability to ameliorate memory impairment and cognitive decline in rat models of Alzheimer's disease induced by scopolamine. (Rac)-TZ3O is valuable for research into neurodegenerative conditions, particularly in studying the mechanisms underlying Alzheimer's disease and potential therapeutic interventions. -
Synthetic Flavoring Substance
Phenylethyl isovalerate functions primarily as a synthetic flavoring substance. Research indicates that prolonged low-dose exposure may elevate the activity of alanine aminotransferase (ALT) and increase serum sulfhydryl group levels, while simultaneously decreasing cholinesterase (ChE) activity. This compound is relevant for studies involving flavoring agents and their metabolic effects, aiding in the exploration of biochemical pathways related to liver function and neurotransmitter systems. -
Cholinesterase (ChE) Inhibitor
Cyclopenin is a cholinesterase (ChE) inhibitor that effectively modulates acetylcholine levels by preventing its breakdown. This compound exhibits significant biological activity in the study of neurodegenerative diseases and offers potential applications in the examination of cognitive disorders. Researchers can leverage Cyclopenin’s properties for investigations into synaptic transmission and cholinergic signaling pathways. -
AChE Inhitibor
AChE-IN-98 is a potent acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 7.3 μM for human AChE. As a derivative of coumarin, it demonstrates significant biological activity relevant to the modulation of cholinergic neurotransmission. This compound is primarily utilized in research focused on Alzheimer's disease, providing insights into potential therapeutic strategies targeting cognitive decline. -
ChE/MAO-A Inhibitor
Desoxypeganine is a potent alkaloid that serves as an inhibitor of cholinesterase (both BChE and AChE) as well as a selective inhibitor of monoamine oxidase A (MAO-A), exhibiting IC50 values of 2, 17, and 2 μM, respectively. This compound is primarily utilized in research related to alcohol abuse, offering valuable insights into the underlying mechanisms of addiction and potential therapeutic approaches. Its dual inhibitory action positions Desoxypeganine as a significant tool in the study of neurochemical pathways involved in substance use disorders. -
Acetylcholinesterase Inhibitor
ω-Hydroxydigitoemodin is an anthraquinone derivative that functions as an acetylcholinesterase inhibitor. This compound exhibits significant anti-acetylcholinesterase activity and has been identified in the marine fungus Trichoderma harzianum XS-20090075. It is utilized in research exploring neurodegenerative diseases and potential therapeutic approaches targeting cholinergic signaling pathways. -
AChE/BChE Inhibitor
AChE/BChE-IN-3 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 6.08 μM and 0.383 μM against electric eel AChE and equine serum BChE, respectively. This compound demonstrates effective inhibition of cholinesterases, which are important targets in studies related to neurodegenerative diseases and pesticide exposure. AChE/BChE-IN-3 is valuable for research applications focused on understanding cholinergic signaling and developing therapeutic strategies for conditions such as Alzheimer's disease. -
AChE Inhibitor
AChE-IN-30 is an acetylcholinesterase (AChE) inhibitor with an IC50 value of 4.4 μM. It exhibits neuroprotective properties by inhibiting H2O2-induced apoptosis through the reduction of intracellular reactive oxygen species (ROS) accumulation. This compound is valuable for research into Alzheimer's disease and related neurodegenerative disorders. -
Indole Alkaloid
Plasiaticine B is an indole alkaloid isolated from Plantago asiatica. It demonstrates low cytotoxicity in HL-60, A-549, and MCF-7 cell lines, with an IC50 greater than 40 μM. Additionally, Plasiaticine B exhibits minimal inhibitory activity on acetylcholinesterase (AChE), with an inhibition rate below 60%. This compound may be utilized in research exploring the biological roles of indole alkaloids and their potential therapeutic applications. -
BChE Inhibitor
Bisnorcymserine is a potent inhibitor of butyrylcholinesterase (BChE) with an IC50 value of 0.228 nM. This compound effectively reduces levels of amyloid-β peptide (Aβ) and has demonstrated therapeutic potential in ameliorating symptoms of Alzheimer's Disease in aged rat models. Bisnorcymserine's ability to penetrate the blood-brain barrier makes it a valuable tool for research in neurodegenerative disorders. -
BChE Inhibitor
BChE-IN-12 is a non-competitive inhibitor of butyrylcholinesterase (BChE) with an IC50 value of 2.3 μM. Isolated from Bletilla striata, this compound demonstrates significant inhibitory activity that can aid in the investigation of cholinergic dysfunction. BChE-IN-12 is particularly relevant for research applications focused on Alzheimer's disease and other cognitive disorders where BChE modulation may play a therapeutic role. -
Cholinesterases Reactivator
MMB-4 is an oxime compound that functions as a reactivator of cholinesterases inhibited by organophosphate exposure, including agents such as Sarin and Soman. It exhibits significant biological activity in restoring the enzymatic function of cholinesterases, thereby countering the toxic effects associated with organophosphate poisoning. This capability makes MMB-4 a valuable tool for research in toxicology and pharmacology, particularly in the study of antidotal therapies for nerve agent exposure. -
Alkaloid Compound
Lycodoline is an alkaloid compound known for its inhibition of butyrylcholinesterase (BChE), with an IC50 value of 667 μM. This specific activity makes Lycodoline a valuable tool in studies focused on neurodegenerative diseases where cholinergic signaling is disrupted. Its properties may contribute to research on cognitive enhancement and therapeutic strategies targeting cholinergic pathways. -
AChE/BChE Inhibitor
AChE/BChE-IN-4 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 792 nM for human AChE and 2.2 nM for human BChE. This compound is capable of crossing the blood-brain barrier, making it a valuable tool for research into neurodegenerative diseases such as Alzheimer's. Its selective inhibition profile provides insights into cholinergic system modulation and potential therapeutic applications. -
NTE Inhibitor
KBR 2822 is a selective inhibitor of neurological target esterase (NTE) and exhibits inhibitory activity against acetylcholinesterase (AChE). This compound is utilized in research to investigate the mechanisms of neurological damage and the role of NTE in neurotoxicity. While KBR 2822 can exacerbate neurological damage under specific conditions, it does not induce neurological disease when administered alone without direct neurotoxic effects or biochemical alteration. -
AChE Inhibitor
AChE-IN-8 is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 1.95 μM. It is primarily utilized in research focused on Alzheimer's disease, where inhibition of AChE can aid in the enhancement of acetylcholine levels in the synaptic cleft. This compound serves as a valuable tool for investigations into therapeutic strategies for cognitive decline associated with neurodegenerative disorders. -
Anticholinergic Agent
Pridinol is a muscarinic acetylcholine receptor (mAChR)-directed anticholinergic agent that demonstrates muscle relaxant properties. This compound effectively reduces impulse conduction to spinal motor neurons, resulting in decreased muscle contractures associated with various musculoskeletal disorders. Pridinol is valuable for research applications focused on both central and peripheral origins of muscle dysfunction, making it a significant tool for the study of neuromuscular conditions. -
AChE Inhibitor
ACHE-IN-38 hydrochloride is a potent acetylcholinesterase (AChE) inhibitor that effectively reduces the breakdown of the neurotransmitter acetylcholine. By enhancing cholinergic transmission, this compound shows promise in alleviating memory deficits associated with Alzheimer's Disease. It serves as a valuable tool for research into neurodegenerative disorders and the pharmacological modulation of cognitive functions. -
BuChE Inhibitor
BuChE-IN-12 is a selective butyrylcholinesterase (BuChE) inhibitor with an IC50 of 0.52 µM, targeting the catalytic and peripheral anionic sites. This compound has demonstrated potential against oxidative stress, making it valuable for exploring therapeutic approaches in Alzheimer's disease research. BuChE-IN-12 serves as a useful tool for investigating the role of BuChE in neurotransmission and related neurodegenerative conditions. -
Insecticide
Dimefluthrin is an insecticide that primarily targets the nervous system of insects. It demonstrates significant contact toxicity against large red imported fire ant workers and facilitates horizontal transfer among individuals, resulting in secondary mortality in recipient ants. Additionally, Dimefluthrin acts as a neurodevelopmental toxicant, inhibiting acetylcholinesterase activity, which disrupts neurotransmitter function. This compound is valuable in research applications related to pest control and the study of neurotoxic effects in insect populations. -
BChE Inhibitor
S21-1011 is a selective inhibitor of butyrylcholinesterase (BChE) with IC50 values of 0.059 μM for equine BChE and 0.162 μM for human BChE. This compound demonstrates effective blood-brain barrier permeability and favorable pharmacokinetic properties. Additionally, S21-1011 exhibits anti-inflammatory activity by activating the keap1-Nrf2-ARE signaling pathway, with an EC50 of 23.48 μM for antioxidant response element activation. Its potential to ameliorate cognitive impairments in murine models of Alzheimer’s disease makes it relevant for neurodegenerative research applications. -
AChE Inhibitor
AChE-IN-17 is a potent acetylcholinesterase (AChE) inhibitor with an IC50 value of 28.98 μM. This compound demonstrates significant neuroprotective effects by preventing hydrogen peroxide-induced cell death in PC12 cells. AChE-IN-17 is valuable for research focused on neurodegenerative diseases, providing insights into therapeutic strategies for conditions characterized by cholinergic dysfunction. -
AChE/Nrf2 Modulator
AChE/Nrf2 Modulator 1 is an orally active compound that targets both acetylcholinesterase (AChE) and the nuclear factor erythroid 2-related factor 2 (Nrf2). It exhibits significant Nrf2 inductive activity along with potent AChE inhibitory effects, presenting IC50 values of 0.07 μM for eel AChE and 0.38 μM for human AChE. This compound is primarily utilized in research focused on Alzheimer's disease, providing insights into neuroprotective mechanisms and cholinergic system modulation. -
AChE Inhibitor
AChE-IN-6 is a potent acetylcholinesterase (AChE) inhibitor, exhibiting significant inhibitory activity against both eel AChE (IC50 = 0.20 μM) and human AChE (IC50 = 37.02 nM). Additionally, AChE-IN-6 demonstrates robust anti-amyloid beta activity, with IC50 values of 1.92 μM for inhibiting self-induced Aβ1-42 aggregation and 1.80 μM for promoting disaggregation of Aβ1-42 fibrils. These properties suggest its utility in Alzheimer's disease research, particularly in exploring therapeutic strategies targeting cholinergic dysfunction and amyloid pathology. -
Cholinesterase Inhibitor
BChE-IN-45 is a competitive cholinesterase inhibitor designed to target butyrylcholinesterase (BChE) and acetylcholinesterase (AChE). It demonstrates an inhibition constant (Ki) of 11.13 μM for dual action, with IC50 values of 13.8 μM for BChE and 35.63 μM for AChE. BChE-IN-45 is a valuable tool for research focused on neurodegenerative conditions, particularly Alzheimer's disease, enabling the exploration of cholinergic system modulation. -
AChE/BChE Inhibitor
AChE/BChE-IN-11 is a potent dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with IC50 values of 70 μM and 71 μM, respectively. This natural product, derived from artichoke leaves, exhibits significant biological activity relevant to neurodegenerative disorders. AChE/BChE-IN-11 can be utilized in studies investigating Alzheimer's disease and other conditions linked to cholinergic dysfunction, facilitating the exploration of therapeutic options targeting cholinesterase enzymes. -
AChE/BuChE Inhibitor
AChE/BuChE-IN-1 is a selective butyrylcholinesterase (BuChE) inhibitor that exhibits an IC50 of 0.48 μM for BuChE and 7.16 μM for acetylcholinesterase (AChE). This compound demonstrates significant scavenging activity against reactive oxygen species (·OH) with an IC50 of 0.1674 μM and effectively inhibits Aβ1-42 aggregation under various conditions (self-, Cu2+-induced, AChE-induced). With high blood-brain barrier permeability and bioavailability, alongside low cytotoxicity, AChE/BuChE-IN-1 is valuable for research into Alzheimer’s disease pathophysiology and therapeutic strategies. -
AChE Inhibitor
Acotiamide hydrochloride is a selective and reversible inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 of 1.79 μM. This compound is known to enhance gastric contractility and promote accelerated gastric emptying. Acotiamide hydrochloride is primarily utilized in research focused on functional dyspepsia related to gastric motility dysfunction and intestinal inflammation. -
Acetylcholinesterase Inhibitor
Eseramine is a weak acetylcholinesterase inhibitor with an IC50 value of 9300 nM. Its primary mechanism involves the modulation of acetylcholinesterase activity, making it relevant for research into conditions such as glaucoma, myasthenia gravis, and organophosphate poisoning-related protection. Eseramine serves as a valuable tool in the exploration of therapeutic strategies targeting acetylcholinesterase regulation in various neurological disorders. -
AChE Inhibitor
AChE-IN-92 is a highly selective acetylcholinesterase (AChE) inhibitor with an IC50 of 4.6 nM. By inhibiting AChE activity, it effectively prevents the hydrolysis of acetylcholine, leading to increased synaptic levels of this neurotransmitter. AChE-IN-92 is a valuable tool for research focusing on Alzheimer’s disease and related neurodegenerative disorders. -
Acetylcholinesterase Inhibitor
AChE-IN-113 is a selective inhibitor of acetylcholinesterase, exhibiting a Ki value of 8.3 μM against electric eel acetylcholinesterase. This compound is utilized in research focused on Alzheimer's disease, allowing for the investigation of cholinergic signaling pathways and the potential therapeutic implications in neurodegeneration. Its specificity for acetylcholinesterase makes it a valuable tool for studying enzyme activity and related disorders. -
Cholinesterase (ChE) Inhibitor
Picfeltarraenin IV is a triterpenoid compound that acts as an acetylcholinesterase (AChE) inhibitor. This compound exhibits significant potential for modulating cholinergic neurotransmission, making it relevant for studies related to neurological conditions. Additionally, Picfeltarraenin IV demonstrates biological activities that may be beneficial in the treatment of herpes infections, cancer, and inflammatory disorders. Its diverse therapeutic applications make it a valuable reagent for research in pharmacology and medicinal chemistry. -
AChE Inhibtor
AChE-IN-69 is a potent acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 of 1.67 µM. This compound is primarily utilized in research related to Alzheimer’s disease, offering insights into the modulation of cholinergic signaling. Its inhibitory activity makes it a valuable tool for studying cholinergic dysfunction and potential therapeutic interventions in neurodegenerative conditions. -
AChE Inhibitor
Chondrocurine, an alkaloid derived from the roots of Cissampelos pareira Linn., functions as an acetylcholinesterase (AChE) inhibitor with an IC50 of 7.46 μM. This compound demonstrates significant activity in modulating cholinergic signaling, making it a valuable tool for studying neuropharmacology and related fields. Its application in research may extend to investigations of neurodegenerative diseases and neuromuscular junction disorders. -
AChE/BChE/MAO-B Inhibitor
AChE/BChE/MAO-B-IN-5 is a multitarget inhibitor of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase B (MAO-B). With IC50 values of 0.24 µM, 6.29 µM, and 0.11 µM for AChE, BChE, and MAO-B, respectively, this compound demonstrates potent inhibition of key enzymes involved in cholinergic neurotransmission and monoamine metabolism. AChE/BChE/MAO-B-IN-5 is particularly relevant for research into neurodegenerative diseases, including Alzheimer's disease, due to its ability to penetrate the blood-brain barrier. -
AChE Inhibitor
2-Hydroxyalbrassitriol is a potent inhibitor of acetylcholinesterase (AChE) with an IC50 of 35.97 μM. This compound is utilized in research focused on neurodegenerative diseases and cognitive function by modulating cholinergic signaling. Its inhibition of AChE makes it a valuable reagent for studies investigating potential therapeutic strategies for conditions such as Alzheimer's disease.
